A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)
- Bernicker, Eric H. (PI)
- Barrios, Roberto (Key Personnel)
- Chan, Edward Y. (Key Personnel)
- Chang, Jenny C. (Key Personnel)
- Heyne, Kirk (Key Personnel)
- Kim, Min Peter (Key Personnel)
- Niravath, Polly A. (Key Personnel)
- Singh, Monisha (Key Personnel)
- Zhang, Jun (Key Personnel)
Project: Clinical Trial